Best Practices in lung cancer – November 2017 Vol 8

Letters from Lillie

In Recognition of Lung Cancer Awareness Month


Dear Navigators, The principles of navigation began in the discipline of breast cancer. After observing the tremendous success of removing barriers to care as an effective method to improve clinical [ Read More ]

Interview with the Innovators

A Day in the Life of a Thoracic Navigator

An Interview with Wendy Brooks, RN, ONN-CG(T), HCA Midwest at Research Medical Center

Navigation is on the march and being utilized in many oncology disciplines as the benefits of implementing navigation tactics are being recognized in the oncology community at large. Although navigation [ Read More ]

Lung Cancer

Lung Cancer. Now What? Plans and How We “Navigate” Them

Amy M. Norton, RN, MSN, ONN-CG(T)1; Dawn M. Deacon, RN, BSN, OCN, ONN-CG1; Wendy L. Brooks, RN, ONN-CG(T)1; Erin L. Terwilliger, RN, BSN, ONN-CG2
1Sarah Cannon Cancer Institute – HCA Midwest Division; 2AstraZeneca Pharmaceuticals LP 

Ali Mokdad, PhD, reported in JAMA that “cancer mortality rates in the United States dropped from 240.2 to 192.0 per 100,000 population between 1980 and 2014.”1 However, according to the [ Read More ]

American Cancer Society

Academy of Oncology Nurse & Patient Navigators and the American Cancer Society (ACS) Forge Partnership

Alliance will advance educational and professional development opportunities for ACS Oncology Navigators

It has been proved that teamwork is vital in the battle against cancer. This is a fact that the Academy of Oncology Nurse & Patient Navigators (AONN+) and the American [ Read More ]


Osimertinib Improves Progression-Free Survival in Patients with EGFR-Mutated Lung Cancer

Osimertinib improves progression-free survival by 54% compared with standard first-line therapy in patients with EGFR-mutated non–small cell lung cancer (NSCLC), according to late-breaking results from the FLAURA trial presented at [ Read More ]

Lung Cancer

Practice-Changing Results: PD-L1 Inhibitor Consolidation Therapy for NSCLC

Durvalumab, a PD-L1 inhibitor, improved progression-free survival (PFS) by 11.2 months compared with placebo in patients with locally advanced, unresectable stage III non–small cell lung cancer (NSCLC) that did not [ Read More ]

Lung Cancer

Regular CT Scans During Follow-Up May Not Be Necessary

Findings of a randomized study suggest that follow-up CT scans may not be needed every 3 to 6 months during the first 2 years after surgery for patients with non–small [ Read More ]